Establishment of new immunotherapy targeting novel co-inhibitory molecule DC-HIL against canine malignant melanoma
Project/Area Number |
15K18798
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Multi-year Fund |
Research Field |
Veterinary medical science
|
Research Institution | Nippon Veterinary and Life Science University |
Principal Investigator |
Tamura Kyoichi 日本獣医生命科学大学, 獣医学部, 助教 (00722282)
|
Project Period (FY) |
2015-04-01 – 2017-03-31
|
Project Status |
Completed (Fiscal Year 2016)
|
Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2015: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
Keywords | 犬 / 悪性黒色腫 / 免疫抑制 / DC-HIL |
Outline of Final Research Achievements |
Our aim of this project is the establishment of new immunotherapy targeting novel co-inhibitory molecule DC-HIL against canine malignant melanoma. DC-HIL expressed by malignant melanoma cells acted in an inhibitory manner in the tumor immune reaction and showed that tumor growth was promoted. In a case of canine malignant melanoma, we found that DC-HIL in which tumor cells are expressed is involved in the immunosuppression of tumor-bearing individuals and that the prognosis may be poor. In addition, we revealed that anti-dog DC-HIL antibody can inhibit immunosuppressive function by DC-HIL expressed by canine malignant melanoma cells.
|
Report
(3 results)
Research Products
(11 results)
-
-
[Journal Article] Molecular Characterization of the Cytidine Monophosphate-N-Acetylneuraminic Acid Hydroxylase (CMAH) Gene Associated with the Feline AB Blood Group System.2016
Author(s)
Omi T, Nakazawa S, Udagawa C, Tada N, Ochiai K, Chong YH, Kato Y, Mitsui H, Gin A, Oda H, Azakami D, Tamura K, Sako T, Inagaki T, Sakamoto A, Tsutsui T, Bonkobara M, Tsuchida S, Ikemoto S.
-
Journal Title
PLoS One
Volume: 11
Issue: 10
Pages: e0165000-e0165000
DOI
Related Report
Peer Reviewed / Open Access
-
-
-
-
-
-
-
-
-